Cellulite proposed as a biomarker for metabolic dysfunction, redefining body remodeling beyond GLP-1R agonists

Traditionally viewed as a cosmetic issue, cellulite may reflect deeper interactions between adipose tissue biology, dermal architecture, and metabolic status. Current standard-of-care for obesity and metabolic dysfunction, including GLP-1 receptor agonists like tirzepatide, effectively improves weight and insulin sensitivity but often fails to restore dermal structure or reduce persistent cellulite. This gap highlights the need for approaches that address both systemic metabolic health and local dermal remodeling, moving beyond surface-level aesthetic treatments to consider cellulite as a potential indicator of underlying physiological imbalance.

This editorial introduces the Cellulite Removal Medical Protocol-G21 (CRMP-G21) as a conceptual framework, not a validated therapeutic standard. It proposes an integrative approach to cellulite, moving beyond its traditional aesthetic classification to consider it a potential biomarker for metabolic-dermal dysfunction. The concept aims to combine systemic metabolic optimization strategies with targeted local dermal restoration techniques. This framework emphasizes the interplay between insulin resistance, chronic low-grade inflammation, adipose tissue dysfunction, impaired microvascular function, and altered collagen organization in cellulite development.

The editorial posits a 'metabolic-dermal axis' where cellulite serves as a visible manifestation of systemic metabolic health interacting with local tissue integrity. It highlights that while GLP-1 receptor agonists significantly improve metabolic parameters and reduce adiposity, they do not consistently resolve dermal issues like skin laxity or cellulite. The proposed CRMP-G21 concept integrates metabolic optimization with specific dermal restoration strategies, acknowledging that both systemic and local factors contribute to cellulite. This framework suggests that addressing underlying metabolic dysfunctions, such as insulin resistance and chronic inflammation, alongside direct dermal interventions, could lead to more comprehensive improvements. The core idea is that persistent cellulite post-weight loss signals an incomplete restoration of tissue quality, necessitating a dual approach.

The CRMP-G21 concept redefines cellulite as a potential clinical marker of metabolic-dermal dysfunction, advocating for combined systemic metabolic optimization and targeted dermal restoration.